What is the most common medical treatment for acute ischemic stroke?

What is the most common medical treatment for acute ischemic stroke?

• A. Aspirin
• B. Dextran
• C. Heparin
• D. rtPA

Answer: (D)

The most common medical treatment for acute ischemic stroke is recombinant tissue plasminogen activator (rtPA). rtPA is a thrombolytic agent that works by dissolving the blood clot that is blocking the flow of blood to the brain, thereby restoring perfusion and minimizing neurological damage. The timely administration of rtPA is crucial, as it must be given within a narrow therapeutic window from the onset of stroke symptoms, usually within 4.5 hours. rtPA is favored over other treatments in the acute setting due to its efficacy in significantly reducing long-term disability and improving outcomes in patients who are eligible for this intervention. Given that it directly targets the underlying cause of ischemic stroke—a blood clot—it represents the most effective medical treatment available. In contrast, other options like aspirin, although useful in secondary prevention and reducing the risk of further strokes, do not actively dissolve clots and are not appropriate for acute treatment. Dextran and heparin are also not standard treatments for acute ischemic stroke; while heparin may be used in certain conditions like venous thromboembolism, it is not standard for this type of stroke and does not address the immediate need to dissolve clots in the brain. Therefore, rtPA stands out as

The most common medical treatment for acute ischemic stroke is recombinant tissue plasminogen activator (rtPA). rtPA is a thrombolytic agent that works by dissolving the blood clot that is blocking the flow of blood to the brain, thereby restoring perfusion and minimizing neurological damage. The timely administration of rtPA is crucial, as it must be given within a narrow therapeutic window from the onset of stroke symptoms, usually within 4.5 hours.

rtPA is favored over other treatments in the acute setting due to its efficacy in significantly reducing long-term disability and improving outcomes in patients who are eligible for this intervention. Given that it directly targets the underlying cause of ischemic stroke—a blood clot—it represents the most effective medical treatment available.

In contrast, other options like aspirin, although useful in secondary prevention and reducing the risk of further strokes, do not actively dissolve clots and are not appropriate for acute treatment. Dextran and heparin are also not standard treatments for acute ischemic stroke; while heparin may be used in certain conditions like venous thromboembolism, it is not standard for this type of stroke and does not address the immediate need to dissolve clots in the brain. Therefore, rtPA stands out as